What Will Happen to Avexis Inc (NASDAQ:AVXS) Next? The Stock Has Decline in Shorts

May 17, 2018 - By Darrin Black

The stock of Avexis Inc (NASDAQ:AVXS) registered a decrease of 1.59% in short interest. AVXS’s total short interest was 2.99 million shares in May as published by FINRA. Its down 1.59% from 3.04 million shares, reported previously. With 1.04M shares average volume, it will take short sellers 3 days to cover their AVXS’s short positions. The short interest to Avexis Inc’s float is 11.36%.

The stock increased 0.08% or $0.18 during the last trading session, reaching $217.83. About 613,648 shares traded. AveXis, Inc. (NASDAQ:AVXS) has risen 59.28% since May 17, 2017 and is uptrending. It has outperformed by 47.73% the S&P500.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $8.02 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

More notable recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Globenewswire.com which released: “Novartis completes tender offer for all outstanding shares of AveXis, Inc.” on May 15, 2018, also Streetinsider.com with their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018, Streetinsider.com published: “Novartis top lawyer exits in wake of Trump attorney deal” on May 16, 2018. More interesting news about AveXis, Inc. (NASDAQ:AVXS) were released by: Nasdaq.com and their article: “AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology” published on April 19, 2018 as well as Globenewswire.com‘s news article titled: “AveXis Provides Update on Proposed Acquisition by Novartis AG” with publication date: May 01, 2018.

AveXis, Inc. (NASDAQ:AVXS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.